Real-World Outcomes of Resected EGFR-Mutated NSCLC patients treated with Adjuvant EGFR-TKI in China

Trial Identifier:	D5164R00012
Sponsor:	AstraZeneca
Start Date:	June 2026
Primary Completion Date:	June 2031
Study Completion Date:	June 2031
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Guangzhou, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.